AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

ESOMEPRAZOLE 40.000 Mg ;

30 registrations across 1 African market— 30 active

Markets with ESOMEPRAZOLE 40.000 Mg ;

Recent registrations

Brand / ProductMarketHolderStatusExpires
BIORAZO 40mg
delayed release hard gelatin capsule
🇪🇬EgyptSAJA Pharmaceuticals Egypt - SAJAactive
Neximash 40 mg
Enteric coated granules for delayed release oral suspension
🇪🇬EgyptMash for pharmaceutical Industries and cosmetic - mash premiereactive
Nexium IV
Powder for Solution for Injection
🇪🇬EgyptAstrazeneca scientific officeactive
NEXIUM
Gastro resistant tablet
🇪🇬EgyptAstraZeneca Egypt for Pharmaceutical Industriesactive
AIG ESOMEPRAZOLE
Hard Gelatin Capsules Containing Delayed Release Pellets
🇪🇬EgyptPLANET CUREactive
Esomeprazole – Eva Pharma 40 mg
Powder for Solution for I.V Infusion
🇪🇬EgyptEva pharma for Pharmaceuticals and Medical Appliances - Eva Pharmaactive
Esogerdazole 40mg DR
Delayed release enteric coated pellets in hard gelatin capsule
🇪🇬Egyptal rowad for pharmaceutical industriesactive
Esopiroxan 40mg
Delayed release enteric coated pellets in hard gelatin capsule
🇪🇬Egyptal andalous for pharmaceutical industriesactive
Esomeprazole – Eva Pharma
Enteric Coated Tablet
🇪🇬EgyptEva pharma for Pharmaceuticals and Medical Appliances - Eva Pharmaactive
PACIFIAL 40 mg
Hard Gelatin Capsules Containing Delayed Release Pellets
🇪🇬EgyptSIGMA PHARMACEUTICAL INDUSTRIESactive
PACIFIAL 40 mg
Hard Gelatin Capsules Containing Delayed Release Pellets
🇪🇬EgyptSIGMA PHARMACEUTICAL INDUSTRIESactive
AIG ESOMEPRAZOLE
Hard Gelatin Capsules Containing Delayed Release Pellets
🇪🇬EgyptPLANET CUREactive
Esomeprazole – Eva Pharma 40 mg
Powder for Solution for I.V Infusion
🇪🇬EgyptEva pharma for Pharmaceuticals and Medical Appliances - Eva Pharmaactive
Esogerdazole 40mg DR
Delayed release enteric coated pellets in hard gelatin capsule
🇪🇬Egyptal rowad for pharmaceutical industriesactive
Esopiroxan 40mg
Delayed release enteric coated pellets in hard gelatin capsule
🇪🇬Egyptal andalous for pharmaceutical industriesactive
Esomeprazole – Eva Pharma
Enteric Coated Tablet
🇪🇬EgyptEva pharma for Pharmaceuticals and Medical Appliances - Eva Pharmaactive
Esmorap® 40 mg
Delayed Release Granules for Oral Suspension
🇪🇬EgyptAUG Pharmaactive
Esmorap
Powder for Solution for I.V Infusion
🇪🇬EgyptAUG Pharmaactive
ESMORAP 40 mg
Hard Gelatin Capsules
🇪🇬EgyptAUG Pharmaactive
STOMOPRAL 40 mg
Hard gelatin capsules containing enteric coated pellets
🇪🇬EgyptFUTURE PHARMACEUTICAL INDUSTRIES-EGYPTactive
NEXIUM
Gastro resistant tablet
🇪🇬EgyptAstraZeneca Egypt for Pharmaceutical Industriesactive
Esmorap
Powder for Solution for I.V Infusion
🇪🇬EgyptAUG Pharmaactive
Esmorap® 40 mg
Delayed Release Granules for Oral Suspension
🇪🇬EgyptAUG Pharmaactive
Nexium IV
Powder for Solution for Injection
🇪🇬EgyptAstrazeneca scientific officeactive
ESMORAP 40 mg
Hard Gelatin Capsules
🇪🇬EgyptAUG Pharmaactive
Megaprazole 40 mg
Lyophilized Powder for Reconstitution for I.V Infusion
🇪🇬EgyptChemipharm Pharmaceutical Industriesactive
Atmiprazole 40 mg
Hard Gelatin Capsules Containing Delayed Release Pellets
🇪🇬EgyptATM Pharmaceutical Industries, Import and Exportactive
Exeedogast
Delayed release capsule containing enteric coated pellets
🇪🇬EgyptNaplex Pharmaceuticalsactive
KLEMAZICE 40mg
Hard Gelatin Capsules Containing Delayed Release Pellets
🇪🇬EgyptSpimaco Misr for pharmaceutical industriesactive
STOMOPRAL 40 mg
Hard gelatin capsules containing enteric coated pellets
🇪🇬EgyptFUTURE PHARMACEUTICAL INDUSTRIES-EGYPTactive

ESOMEPRAZOLE 40.000 Mg ; in Africa — Regulatory Overview

ESOMEPRAZOLE 40.000 Mg ; is registered across 1 African markets with 30 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Egypt. AfricaRegulatory refreshes this data daily from official government sources.

Of the 30 registrations, 30 (100%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.